3 min read
Measuring What Can't Be Seen: How PTSD Clinical Trials Prove a Drug Works
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
We provide impactful strategies and solutions to meet your outsourcing needs in order to plan and run your next clinical trial, program or regulatory submission project. Our 25 years of experience helping emerging and small to mid-size biotech firms take their products from IND to NDA approval are worth taking a look at. In 2018 alone, our team prepared the regulatory submissions for 12% of the NMEs approved by the FDA. And, many of those programs we supported since the writing of the study protocols and IND.
Whether you have a compound and need to get started on your IND, or need to recruit patients quickly to get your early phase trials running or just need medical writing or biostatistical support for your programs - Veristat can help.
Speak with us at the Outsourcing in Clinical Trials Southeast conference in Durham, NC on March 26-27, 2019! And, did you know, if you are a Director, VP or C-Suite member of a biotech, pharmaceutical or medical device firm, you can register for free.
Schedule a meeting by filling out the form on the right. Find out how we can help you advance your next clinical trial or regulatory submission to successful outcomes. Or, read some of our recent insightful perspectives.
3 min read
Apr 27, 2026 Veristat Blog
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
3 min read
Apr 24, 2026 Veristat Blog
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...